Ralinepag vs Treprostinil (Tyvaso DPI)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Ralinepag

Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.

Phase 3 in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT03626688 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).

Next expected readout: December 2026 · NCT03683186 (registry estimate)

Reported efficacy

Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)

Result source: NCT03626688

Treprostinil (Tyvaso DPI)

Marketed by United Therapeutics and partners

Approved in Pulmonary Arterial Hypertensionsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Ralinepag: 5 of 5 rows · Treprostinil (Tyvaso DPI): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRalinepagTreprostinil (Tyvaso DPI)
6MWD - Change
absolute change · m
No placebo or comparator arm
-120 m @ 221wka,b,c,d
NCT02279745 · Phase 2 · registry result, not featured evidence
11.5 m @ 3wka,b,c,d
NCT03950739 · Phase 1 · registry result, not featured evidence
Dropout rate
44.4%e
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
15%
NCT02279160 · Phase 2 · registry result, not featured evidence
—64 mcge
NCT03950739 · Phase 1 · registry result, not featured evidence
show 6 more results
—64 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
—48 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
—48 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
—32 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
—32 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
3.9%Tyvaso to TreT
NCT03950739 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
15.6%e
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
—
NCT02279160 · Phase 2 · registry result, not featured evidence
—64 mcge
NCT03950739 · Phase 1 · registry result, not featured evidence
show 6 more results
—64 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
—48 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
—48 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
—32 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
—32 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
3.9%Tyvaso to TreT
NCT03950739 · Phase 1 · registry result, not featured evidence
Serious AEs
46.7%e
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
10%
NCT02279160 · Phase 2 · registry result, not featured evidence
57.1%64 mcge
NCT03950739 · Phase 1 · registry result, not featured evidence
show 6 more results
4.5%64 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
46.2%48 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
3.7%48 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
50%32 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
0%32 mcg
NCT03950739 · Phase 1 · registry result, not featured evidence
—Tyvaso to TreT
NCT03950739 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
e
headache 64.4%
diarrhoea 37.8%
pain in jaw 33.3%
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
headache 77.5% (placebo 28.6%)
nausea 50% (placebo 23.8%)
diarrhoea 47.5% (placebo 14.3%)
NCT02279160 · Phase 2 · registry result, not featured evidence
64 mcge
fatigue 23.8%
arthralgia 19%
back pain 19%
NCT03950739 · Phase 1 · registry result, not featured evidence
show 5 more results
64 mcg
cough 31.8%
headache 18.2%
diarrhoea 9.1%
NCT03950739 · Phase 1 · registry result, not featured evidence
48 mcg
dyspnoea 38.5%
covid-19 26.9%
dizziness 23.1%
NCT03950739 · Phase 1 · registry result, not featured evidence
48 mcg
cough 40.7%
headache 14.8%
dyspnoea 7.4%
NCT03950739 · Phase 1 · registry result, not featured evidence
32 mcg
dyspnoea 100%
headache 100%
nausea 100%
NCT03950739 · Phase 1 · registry result, not featured evidence
32 mcg
acute respiratory failure 0%
anaemia 0%
anxiety 0%
NCT03950739 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 1.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 221 weeks versus 3 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ralinepag

PVR Change Dyn S Cm5 -52.2 seconds
absolute change · seconds
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Time to First Clinical Worsening Event 13.04 months
time to event · months
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence · converted to months from 56.5 weeks as posted
6MWD - Change 37 m
absolute change · m
No placebo or comparator arm
End of Study (Time of Discontinuation of Study by Sponsor)
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Output 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Index Change L/Min M2 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Pulmonary Arterial Pressure -2 mmHg
absolute change · mmHg
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
PVR 514.6 vs 512 placebo cm @ 22wk
absolute change · cm
NCT02279160 · Phase 2 · registry result, not featured evidence
6MWD - Change 36.2 vs 29.4 placebo m @ 22wk
absolute change · m
NCT02279160 · Phase 2 · registry result, not featured evidence

Treprostinil (Tyvaso DPI)

PAH Symact Cardiopulmonary Symptoms -0.05 score @ 3wk
absolute change · score
No placebo or comparator arm
Cardiopulmonary Symptoms Domain Score
NCT03950739 · Phase 1 · registry result, not featured evidence
show 1 more result
-0.04 score @ 11wk
Cardiopulmonary Symptoms Domain Score
NCT03950739 · Phase 1 · registry result, not featured evidence
PAH Symact Cardiovascular Symptoms -0.06 score @ 3wk
absolute change · score
No placebo or comparator arm
Cardiovascular Symptoms Domain Score
NCT03950739 · Phase 1 · registry result, not featured evidence
show 1 more result
-0.05 score @ 11wk
Cardiovascular Symptoms Domain Score
NCT03950739 · Phase 1 · registry result, not featured evidence
PAH Symact Physical Impacts -0.14 score @ 3wk
absolute change · score
No placebo or comparator arm
Physical Impacts Domain Score
NCT03950739 · Phase 1 · registry result, not featured evidence
show 1 more result
-0.2 score @ 11wk
Physical Impacts Domain Score
NCT03950739 · Phase 1 · registry result, not featured evidence
PAH Symact Cognitive/Emotional Impacts -0.17 score @ 3wk
absolute change · score
No placebo or comparator arm
Cognitive/Emotional Impacts Domain Score
NCT03950739 · Phase 1 · registry result, not featured evidence
show 1 more result
-0.13 score @ 11wk
Cognitive/Emotional Impacts Domain Score
NCT03950739 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (Tyvaso DPI)'s landscape